Lantheus Holdings is engaged in the development, manufacture and commercialization of diagnostic and therapeutic agents and products that assist clinicians in the diagnosis and treatment of heart disease, cancer and other diseases. Co.'s commercial products include DEFINITY, which is a microbubble ultrasound enhancing agent used in ultrasound exams of the heart, also known as echocardiography exams; and TechneLite, which is a Technetium (Tc-99m) generator that provides the nuclear material used by radiopharmacies to radiolabel Cardiolite, Neurolite and other Tc-99m-based radiopharmaceuticals used in nuclear medicine procedures. The LNTH average annual return since 2015 is shown above.
The Average Annual Return on the LNTH average annual return since 2015 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether LNTH average annual return since 2015 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the LNTH average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|